Jeroen Blokhuis

Jeroen Blokhuis is the director of business development and partnerships at the Parker Institute for Cancer Immunotherapy. He has consulted for diverse companies on challenging projects. His business expertise includes entrepreneurship and innovation; specifically dealing with sourcing and diligence on novel next-generation technologies and generating the strategies for this. His scientific experience includes molecular biology, immunology, and genetics and has a special interest in NK cell biology and the role of NK cells in anti-cancer cell therapies, vaccines and adjuvant development. He enjoys exploring the interface between the tools of molecular biology and their application in immunology. Topics of particular interest to him include: KIR, HLA, Immunotherapy, Immuno-Oncology, checkpoint inhibitors, CAR-T cells, CAR-NK cells, oncolytic viruses, evolution of immune gene families, next-generation protein display technologies, Synthetic Biology and therapeutic aptamers.

Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.